Conference Coverage
Conference Coverage
Five “can’t miss” oncologic emergencies
All patients with suspected leukemias should be admitted.
Conference Coverage
TKI discontinuation appears safe in CML
NEW YORK – Evidence mounts for
Conference Coverage
Will quad therapy become the new standard in myeloma?
NEW YORK – Phase 2 studies have shown high response rates for four-drug combinations targeting multiple myeloma.
Conference Coverage
Novel options for treating hairy cell leukemia
NEW YORK –
Conference Coverage
B-cell maturation antigen targeted in myeloma trials
NEW YORK – So far,
Conference Coverage
IMpower133: Atezolizumab plus standard chemotherapy boosted survival in ES-SCLC
Adding atezolizumab to standard first-line ES-SCLC treatment significantly improved overall survival and progression-free survival in the...
Conference Coverage
Breast cancer risk in type 2 diabetes related to adiposity
Women with type 2 diabetes mellitus have a moderately increased risk of breast cancer that appears to be mainly caused by adiposity, not diabetes...
Conference Coverage
Venetoclax promising in unfit elderly AML patients
NEW YORK – Physicians are watching data on venetoclax, which has the potential to treat a subset of patients who can’t tolerate intensive therapy...
Conference Coverage
Antithrombotic strategy 1 year after stenting in AF patients leans toward oral anticoagulant alone
SAN DIEGO – A primary endpoint failed to show noninferiority of oral anticoagulants alone versus anticoagulants plus antiplatelet therapy, but a...
Conference Coverage
PACIFIC trial: Durvalumab improves both OS and PFS in stage III NSCLC
TORONTO – Updated PACIFIC trial results show that durvalumab provides first major OS, PFS advance for stage III NSCLC in decades.
Conference Coverage
Breast cancer patients getting unnecessary scans against recommendations
PHOENIX – Despite ASCO recommendations, many patients with early-stage breast cancers at low metastasis risk have undergone imaging tests for...